Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 Pharmaceutical Investing
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel Pharmaceutical Investing
Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder Company News
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough Pharmaceutical Investing
The Gummy Project Announces Successful Completion of Presale Phase and Official Launch of Shipping Capabilities Across Canada Company News
Eupraxia Pharmaceuticals Recognized as Emerging Life Sciences Company of the Year by Life Sciences British Columbia Life Science Investing
